Food is medicine. However, food today is no longer grown but engineered to enhance palatability which has led to detrimental consequences. The excessive use of sugar in nearly every processed food has transformed our diets, resulting in unsatisfying meals that perpetuate hedonic cravings. This has played a significant role in the rising rates of obesity, type 2 diabetes, cardiovascular disease, autoimmune conditions, and other health issues affecting western societies.

At Palate Therapeutics, we are committed to fostering a healthier society by redefining the way we experience the sweetness in our lives. Our goal is to provide people with a chance to reevaluate and consciously choose healthier food options. Rather than changing the composition of food, we aim to revolutionize how individuals taste and perceive sweetness, ultimately promoting healthier and sustainable eating habits.

Established in 2022 by three accomplished PhD scientists from Georgia Tech & MIT, we are engineering a groundbreaking therapy utilizing oligonucleotides. This therapy has the unique ability to temporarily and reversibly alter how sweet foods taste and how they are metabolized. Unlike conventional methods that modify metabolism after food is consumed, our approach provides a novel strategy to prevent and manage metabolic diseases, restore balanced diets, and enhance overall well-being.

We are a preclinical stage company utilizing a unique mechanism of action targeting taste buds. In mouse models, we have demonstrated gene modulation lasting up to 14 days with a single dose leading to minimal weight gain. Our therapy has the potential to be applied as a mono-therapy or in combination to existing GLP-1 based drugs.